| Bioactivity | WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC)[1]. |
| Invitro | WYJ-2 (0-10 μM) 抑制 THP-1 细胞中 TLR2 和 TLR1 异二聚化，刺激 MyD88 蛋白，激活 NF-κB 信号通路，且无明显细胞毒性[1]。WYJ-2 (0-100 μM) 抑制癌细胞 A549、HeLa、HepG2 和 MCF-7 增殖，IC50 约为 10 μM，诱导癌细胞通过激活 NLRP3 炎性体而发生细胞焦亡 (pyroptosis)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> WYJ-2 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | WYJ-2 (5 mg/kg，腹腔注射，每 2 天一次，共 30 天) 可抑制 A549 异种移植 BALB/c 小鼠的肿瘤生长，且无明显毒性[1]。WYJ-2 (10 mg/kg，腹腔注射，单剂量) 在 BALB/c 小鼠体内半衰期 T1/2 为 3.67 小时，清除率 Cmax 为 497 ± 49 ng/mL[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 3029403-05-9 |
| Formula | C17H9F2N3O4 |
| Molar Mass | 357.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang Y, et al., Design and Synthesis of 3-(2H-Chromen-3-yl)-5-aryl-1,2,4-oxadiazole Derivatives as Novel Toll-like Receptor 2/1 Agonists That Inhibit Lung Cancer In Vitro and In Vivo. J Med Chem. 2024 Mar 18. |